Job Watch

Celgene: Principal Scientist, Bioinformatics / Single-Cell

New Scientist - Bioinformatics - Mon, 2018-07-02 03:57
competitive: Celgene: Seeking a Principal Scientist, Bioinformatics / Single-Cell for the San Diego, CA location. San Diego, California (US)
Categories: Job Watch

PROFESSOR - University of Wisconsin–Madison - Madison, WI

Indeed.com - Bioinformatics - Sun, 2018-07-01 02:58
Doctoral degree (PhD, ScD, or equivalent) in Computer Science, Biomedical Informatics, Bioinformatics, Computational Biology, or a closely related quantitative...
From University of Wisconsin–Madison - Sun, 01 Jul 2018 06:58:52 GMT - View all Madison, WI jobs
Categories: Job Watch

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed)

Funding Opportunity PAR-18-845 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed)

Funding Opportunity PAR-18-846 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional)

Funding Opportunity PAR-18-847 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional)

Funding Opportunity PAR-18-848 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Elucidating the Functional Roles of Non-Coding RNAs in Viral Infectious Diseases (R21 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-18-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory and developmental research projects to uncover functional roles of non-coding RNAs (ncRNAs) in viral infectious diseases. Importantly, the projects should focus on functional characterization and mechanistic studies of previously identified ncRNAs. Applications limited to the discovery or identification of ncRNAs will not be supported under this RFA.

Advancing mAbs to Achieve a Drug-free Sustained HIV Virologic Remission (U01 Clinical Trial Required)

Funding Opportunity RFA-AI-18-022 from the NIH Guide for Grants and Contracts. The Purpose of this Funding Opportunity Announcement is to solicit applications to rapidly implement early clinical trials using native and/or engineered monoclonal antibodies (mAbs) to achieve a drug-free sustained virologic remission in HIV infected individuals.

Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)

Funding Opportunity PA-18-842 from the NIH Guide for Grants and Contracts. The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide-ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental proposal is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)

Funding Opportunity PAR-18-841 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

Paramount Recruitment: Director of Computational Biology, Cancer Immunology

New Scientist - Bioinformatics - Thu, 2018-06-28 04:03
Negotiable: Paramount Recruitment: Director of Computational Biology, Cancer Immunology Connecticut, United States Pharmaceutical, Translational Bioinformatics A global pharmaceu Connecticut, USA
Categories: Job Watch

Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)

Funding Opportunity PAR-18-844 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All proposals should address how the methods would scale to address larger and larger data sets.

Pages

Subscribe to Anil Jegga aggregator - Job Watch